Legal News

U.S. Supreme Court Hearings on Drug Company Settlements
Download PDF
1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)

Reuters reported the U.S. Supreme Court is beginning hearings on arguments during the last week of March 2013 in a case challenging payments provided by brand-name drug manufacturers to generic companies to settle patent lawsuits.

The case involves Solvay Pharmaceutical Inc. and three generic drug manufacturers over Solvay’s AndroGel, a testosterone drug. Solvay Pharmaceuticals, Inc. markets more than 32 drugs in the U.S. The company has one drug in the top 100 drugs by U.S. sales, according to in 2012. Medications for drug companies may be distributed under different names in foreign countries.


The U.S. Supreme Court agreed in late 2012 to review the legality of patent settlements in which pharmaceutical companies that distribute branded drugs give funds to generic-drug manufacturers to postpone the sale of generic versions.

The Federal Trade Commission (FTC) for several years fought patent deals that delay the market of generic drugs. According to the Wall Street Journal, the FTC states the settlements do not allow the public to save billions in less expensive drugs. While the high court’s ruling on the case is projected to increase litigation in the pharmaceutical industry, its impact on patent settlements in other industries is debatable.

At issue is U.S. Supreme Court case is a settlement where Solvay, which is now part of Abbott Laboratories, filed suit against the generic drug manufacturers claiming their plans to market a version of AndroGel infringed Solvay’s patents.

Get JD Journal in Your Mail

Subscribe to our FREE daily news alerts and get the latest updates on the most happening events in the legal, business, and celebrity world. You also get your daily dose of humor and entertainment!!

Solvay settled the patent case by agreeing to give the generic drug makers money to keep their versions off the table until 2015. This was five years prior to the expiration of the AndroGel patent. The FTC challenges the Solvay settlement. According to Reuters, the FTC contends the “pay for delay” transactions or “reverse payments” go against antitrust law and harm consumers by postponing lower priced alternatives to recognized brands.

The 11th U.S. Circuit Court of Appeals went with the drug manufacturers that had patents, and ruled, with a few exceptions, reverse payments relating to patent fights, are immune from the competition laws.

If the U.S. Supreme Court does not side with the 11th U.S. Circuit Court of Appeals, and decides pay for delay payments need to comply with antitrust laws, patent settlements may be scrutinized not just in the drug industry, but also other industries.

According to Reuters, Jeffrey Cross, an antitrust attorney at freeborn & Peters said:  “I don’t see a basis to limit the analysis to brand-name and generic drug settlements.”



Corporate Attorney


Full-Time or Part-Time Corporate Attorney We are a boutique corporate and commercial transactiona...

Apply now

Experienced Family Law and Estate Litigation Attorney


Prominent Ridgewood, NJ Elder Law firm seeking a New Jersey Licensed Attorney with at least two year...

Apply now

Full-Time Litigation Associate

USA-CA-Los Angeles

Downtown Los Angeles law firm seeks a full-time litigation associate.  Ideal candidates should ...

Apply now


USA-CA-Newport Beach

The Newport Beach office of Lee Hong Degerman Kang & Waimey is looking for graduates of accredited l...

Apply now




Search Now

Litigation Associate Attorney


Maitland office of our client seeks litigation associate attorney with 2+ years of experience in def...

Apply Now

Litigation Associate Attorney


Charlotte office of our client seeks associate attorney with 1-3 years of civil litigation. The cand...

Apply Now

Litigation Attorney at Law


Eatontown office of our client seeks litigation attorney at law with experience. The candidate shoul...

Apply Now

Most Popular


To Top